Trevi Therapeutics, Inc. $TRVI Stock Position Boosted by Nan Fung Trinity HK Ltd.

Nan Fung Trinity HK Ltd. raised its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 943.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,082,890 shares of the company’s stock after buying an additional 979,115 shares during the period. Trevi Therapeutics makes up approximately 1.5% of Nan Fung Trinity HK Ltd.’s holdings, making the stock its 26th biggest holding. Nan Fung Trinity HK Ltd.’s holdings in Trevi Therapeutics were worth $15,507,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Oppenheimer & Co. Inc. boosted its stake in shares of Trevi Therapeutics by 0.9% during the third quarter. Oppenheimer & Co. Inc. now owns 100,696 shares of the company’s stock valued at $1,442,000 after purchasing an additional 925 shares during the period. AlphaCentric Advisors LLC increased its stake in Trevi Therapeutics by 4.3% in the 3rd quarter. AlphaCentric Advisors LLC now owns 25,370 shares of the company’s stock worth $363,000 after buying an additional 1,053 shares during the period. KBC Group NV purchased a new position in Trevi Therapeutics in the 1st quarter worth about $29,000. Arizona State Retirement System increased its stake in Trevi Therapeutics by 12.9% in the 2nd quarter. Arizona State Retirement System now owns 26,434 shares of the company’s stock worth $493,000 after buying an additional 3,019 shares during the period. Finally, Sterling Capital Management LLC lifted its holdings in Trevi Therapeutics by 848.7% during the 3rd quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock valued at $51,000 after buying an additional 3,191 shares in the last quarter. 95.76% of the stock is currently owned by institutional investors.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, Director Michael Heffernan sold 39,473 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $15.09, for a total transaction of $595,647.57. Following the transaction, the director directly owned 6,351 shares in the company, valued at $95,836.59. This represents a 86.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.39% of the stock is currently owned by insiders.

Trevi Therapeutics Price Performance

TRVI opened at $13.62 on Friday. Trevi Therapeutics, Inc. has a 12-month low of $9.82 and a 12-month high of $20.22. The business’s fifty day simple moving average is $14.10 and its 200-day simple moving average is $14.47.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Monday, November 9th. The company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). Equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on TRVI shares. Morgan Stanley restated an “overweight” rating and issued a $23.00 target price on shares of Trevi Therapeutics in a research note on Friday, August 7th. JonesTrading raised their target price on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, August 14th. Wall Street Zen downgraded shares of Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. BMO Capital Markets reiterated an “outperform” rating on shares of Trevi Therapeutics in a report on Wednesday, October 7th. Finally, B. Riley Financial boosted their price target on Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Trevi Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $27.08.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.